Price: quote on request. Your total cost is quoted in writing per case.
Written estimate for your caseGet my quote

Is Lynozyfic available in Bahrain? How families get Lynozyfic (linvoseltamab-gcpt)

Creator: Reserve Meds
Published: 2026-10-17

A plain answer for families in Bahrain, checked against FDA, manufacturer and regulator sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Is Lynozyfic available in Bahrain?

Lynozyfic (linvoseltamab-gcpt) is an FDA-approved BCMA x CD3 bispecific antibody for relapsed or refractory multiple myeloma after at least four prior lines. Lynozyfic is not on NHRA's Registered Medicine Price List (version dated 7 September 2026, 5,560 entries) or on its Temporary Importation Medicines List (dated 19 January 2025). We checked both on 17 October 2026. The legal route is a named-patient request: the treating hospital, on your specialist's request, asks the National Health Regulatory Authority (NHRA) for permission to import Lynozyfic for one patient, using the US FDA approval as the reference. Once approved, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy. We do not prescribe.

Registration in Bahrain: not on NHRA's registered list (7 September 2026) or temporary importation list (19 January 2025), checked 17 October 2026.
Legal route: Named-patient import request to NHRA, filed by the treating hospital.
Who applies: a government or private hospital in Bahrain, on the written request of your treating specialist.
Timeline: We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.
Price: Quote on request. Every case gets a written custom quote before you commit.

What Lynozyfic is

Lynozyfic (linvoseltamab-gcpt) is made by Regeneron. The US FDA approved it on 2 July 2025 for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. It is given as an intravenous (IV) infusion, with step-up doses and a 24-hour hospital stay after the first two step-up doses, then weekly and later every two or four weeks.

The FDA gave accelerated approval. Continued approval may depend on a confirmatory trial. It has a boxed warning for cytokine release syndrome (CRS) and neurologic toxicity. In the US it is available only through a restricted safety program (REMS).

It is also approved in the European Union for adults after at least three prior therapies.

Registration status in Bahrain

NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

The legal route in Bahrain

Under NHRA Circular No. (41) of 2020, government and private hospitals must get NHRA's permission before they issue a purchase order for a medicine that is not registered in Bahrain.

The circular asks that the medicine is important and has no registered alternative in Bahrain, is registered with the Gulf Health Council or in a GCC country, is registered with a reference authority such as the US FDA, and is marketed in its country of origin.

Some medicines for rare diseases, emergencies and tumors with no registered alternative can be excused from the registration and marketing conditions, through NHRA's list of emergency medicines or with Board approval.

The request goes to NHRA by email with the application form, a Certificate of Pharmaceutical Product (CPP) or registration certificate from a reference authority, and a Good Manufacturing Practice (GMP) certificate. NHRA's 2022 application form is signed by the importing hospital, the agent or the marketing authorization holder, who takes full responsibility for the product's quality and safety.

Who does what

Your treating specialist decides whether Lynozyfic is right for the patient and writes the letter and prescription.
The hospital checks the route, files any request and is responsible for giving the medicine safely.
The National Health Regulatory Authority (NHRA) decides whether to approve an import of a medicine that is not registered.
Regeneron makes Lynozyfic and decides where it can be supplied.
Reserve Meds coordinates the paperwork, the US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents the hospital will usually need

A letter from the treating specialist: diagnosis, past treatments, and why Lynozyfic is needed
A prescription with the dose and how long treatment should last
Supporting reports, such as pathology, genetic or laboratory results
The hospital's request form and its signed declaration of responsibility
Written consent from the patient or a legal guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

Timeline, step by step

Doctor's letter. Your specialist writes the clinical letter and prescription.
Hospital request. The hospital pharmacy files the request with NHRA.
Regulator decision. NHRA reviews the request and issues an approval or asks for more information.
US sourcing. Our US-licensed wholesale partner supplies the medicine, and it is shipped with the right temperature controls.
Hospital receipt. The medicine is received at the hospital pharmacy, which gives it to the patient.

We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.

What Lynozyfic costs

Quote on request. Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. We do not prescribe, and we do not decide what the regulator approves.

Ask us about Lynozyfic in Bahrain

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is Lynozyfic approved in Bahrain?

Lynozyfic is not on NHRA's Registered Medicine Price List (version dated 7 September 2026, 5,560 entries) or on its Temporary Importation Medicines List (dated 19 January 2025). We checked both on 17 October 2026. The same registered list does include other specialty therapies, such as Zolgensma, Casgevy and Elevidys, so it does cover this kind of medicine. NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

Who applies for permission to use Lynozyfic in Bahrain?

The treating hospital applies to the National Health Regulatory Authority (NHRA), on the written request of your specialist. Families do not apply on their own, and Reserve Meds does not apply for you.

How long does it take to get Lynozyfic in Bahrain?

We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.

How much does Lynozyfic cost?

Quote on request. Your total cost, including shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Can Reserve Meds send Lynozyfic straight to our home?

No. Lynozyfic goes to the hospital pharmacy named in the approval, which then gives it to the patient. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy.

Sources

Checked on 17 October 2026. Regulator rules and lists change. Your hospital pharmacy confirms the current procedure before filing.